Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover dose-ranging study of NVA237 in moderate to severe COPD
NL-OMON34643Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Jun 2010; status: active, not recruiting.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON34643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34643.